Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Fantini

Showing results (101-110 of 106) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 106 results.
Proceedings of the National Academy of Sciences of the United States of America|May 23, 1995
SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanismsN Yahi, J Fantini, S Baghdiguian, et al.
Journal of Virology|September 1, 1994
Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophagesN Yahi, J Fantini, K Mabrouk, et al.
Archives of Biochemistry and Biophysics|December 19, 2001
Characterization of galactosyl glycerolipids in the HT29 human colon carcinoma cell lineP Påhlsson, S L Spitalnik, P F Spitalnik, et al.
Carbohydrate Research|August 17, 2000
Synthesis of single- and double-chain fluorocarbon and hydrocarbon galactosyl amphiphiles and their anti-HIV-1 activityB Faroux-Corlay, L Clary, C Gadras, et al.
Peptides|January 1, 1986
Characterization of the vasoactive intestinal peptide (VIP) binding sites: a biochemical and an immunological approachJ Marvaldi, J Luis, J M Muller, et al.
Journal of Clinical Microbiology|November 24, 1999
Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequencesN Yahi, C Tamalet, C Tourrès, et al.
Pageof 11

Showing results (101-110 of 106) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 106 results.
Proceedings of the National Academy of Sciences of the United States of America|May 23, 1995
SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanismsN Yahi, J Fantini, S Baghdiguian, et al.
Journal of Virology|September 1, 1994
Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophagesN Yahi, J Fantini, K Mabrouk, et al.
Archives of Biochemistry and Biophysics|December 19, 2001
Characterization of galactosyl glycerolipids in the HT29 human colon carcinoma cell lineP Påhlsson, S L Spitalnik, P F Spitalnik, et al.
Carbohydrate Research|August 17, 2000
Synthesis of single- and double-chain fluorocarbon and hydrocarbon galactosyl amphiphiles and their anti-HIV-1 activityB Faroux-Corlay, L Clary, C Gadras, et al.
Peptides|January 1, 1986
Characterization of the vasoactive intestinal peptide (VIP) binding sites: a biochemical and an immunological approachJ Marvaldi, J Luis, J M Muller, et al.
Journal of Clinical Microbiology|November 24, 1999
Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequencesN Yahi, C Tamalet, C Tourrès, et al.
Pageof 11